Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: ALL026
MIFTS: 65

Allergic Hypersensitivity Disease

Categories: Immune diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Allergic Hypersensitivity Disease

About this section

MalaCards integrated aliases for Allergic Hypersensitivity Disease:

Name: Allergic Hypersensitivity Disease 12 15
Hypersensitivity 12 75 44 72
Allergies 15 63
Allergic Disposition 72
Allergic Condition 72
Allergic Reaction 72
Allergic Disease 12
Allergy 17

Classifications:

MalaCards categories:
Anatomical: Immune diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

Disease Ontology 12 DOID:1205
MeSH 44 D006967
NCIt 50 C3114
SNOMED-CT 68 21957007 91232002
ICD10 33 T78.4 T78.40
UMLS 72 C0020517 C0851444 C1527304 more
Sources

Summaries for Allergic Hypersensitivity Disease

About this section
PubMed Health : 63 About allergies: Allergies arise if the body's immune system overreacts to foreign substances (allergens) that are usually harmless in most people, such as pollen or certain foods. The symptoms can vary a lot. In some cases they are quite mild, but they can also be a real nuisance and have a considerable impact in everyday life. Severe allergic reactions may be life-threatening. There are various treatment options for allergies. Some things that trigger allergies (allergens) are easy to avoid, whereas others aren't. Common allergens include the following:

MalaCards based summary : Allergic Hypersensitivity Disease, also known as hypersensitivity, is related to esophagitis, eosinophilic, 1 and bullous pemphigoid, and has symptoms including nausea and vomiting, abdominal pain and pruritus. An important gene associated with Allergic Hypersensitivity Disease is IL5 (Interleukin 5), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Ketotifen and Hydrocortisone have been mentioned in the context of this disorder. Affiliated tissues include testes, skin and t cells, and related phenotypes are hematopoietic system and digestive/alimentary

Disease Ontology : 12 An immune system disease that is an exaggerated immune response to allergens, such as insect venom, dust mites, pollen, pet dander, drugs or some foods.

Wikipedia : 75 Hypersensitivity (also called hypersensitivity reaction or intolerance) refers to undesirable reactions... more...

Sources

Related Diseases for Allergic Hypersensitivity Disease

About this section

Diseases related to Allergic Hypersensitivity Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2185)
# Related Disease Score Top Affiliating Genes
1 esophagitis, eosinophilic, 1 33.3 IL5 IL13 CCL11
2 bullous pemphigoid 32.9 RNASE3 IL5 CCL11
3 sarcoidosis 1 32.8 IL9 IL3 IL13 IFNG CCL17
4 immune system disease 32.5 IL5 IL4 IL10 IFNG
5 autoimmune disease of central nervous system 32.4 IL4 IL10 IFNG CCL5
6 immunodysregulation, polyendocrinopathy, and enteropathy, x-linked 32.4 IL4 IL10 IFNG
7 idiopathic interstitial pneumonia 31.9 IL4 IL13 IFNG
8 dermatitis 31.8 IL5 IL4 IL13 IGHE IFNG CCL17
9 pollen allergy 31.8 RNASE3 IL5 IL3 IL13 EPX
10 urticaria 31.5 TPT1 RNASE3 IGHE HRH1 FCER2
11 bronchitis 31.5 RNASE3 IL5 CCR3 CCL11
12 allergic asthma 31.5 RNASE3 IL9 IL5 IL4 IL13 IL10
13 papillary conjunctivitis 31.5 IL4 CCL11
14 cytokine deficiency 31.5 IL9 IL5 IL13
15 interstitial lung disease 31.5 IL4 IL10 IFNG CCL5 CCL17
16 ige responsiveness, atopic 31.5 RNASE3 IL9 IL5 IL4 IL13 IL10
17 rhinitis 31.5 RNASE3 IL5 IL4 IL13 IGHE HRH1
18 pneumonia 31.5 IL5 IL13 IL10 CCL5 CCL11
19 pulmonary fibrosis, idiopathic 31.4 IL13 IFNG CCL5 CCL17
20 food allergy 31.4 RNASE3 IL5 IL4 IL13 IL10 IFNG
21 contact dermatitis 31.4 IL5 IL4 IL10 IFNG CCL17
22 stevens-johnson syndrome/toxic epidermal necrolysis 31.4 IL5 IL13 IFNG CCR3 CCL5 CCL17
23 esophagitis 31.4 IL5 IL13 CCR3 CCL11
24 giant papillary conjunctivitis 31.3 RNASE3 IL4 CCL11
25 leishmaniasis 31.3 IL5 IL4 IL13 IL10 IFNG
26 egg allergy 31.3 IL5 IL4 IGHE
27 allergic conjunctivitis 31.3 RNASE3 IL5 IL4 IL13 IFNG HRH1
28 milk allergy 31.3 RNASE3 IL5 IL4 IL10 CSN1S1
29 immune deficiency disease 31.2 IL4 IL13 IL10
30 beta-lactam allergy 31.2 IL4 IL13 IL10
31 conjunctivitis 31.2 RNASE3 IL5 IL4 IL13 IFNG HRH1
32 inflammatory bowel disease 31.2 IL4 IL13 IL10 IFNG
33 allergic contact dermatitis 31.2 IL5 IL4 IL10 IFNG CCL17
34 tetanus 31.1 IL5 IL4 IL13 IL10 IFNG
35 extrinsic allergic alveolitis 31.1 IL10 FCER2 CCL5
36 paracoccidioidomycosis 31.1 IL5 IL4 IL10 IFNG
37 neuritis 31.1 IL4 IFNG CCL5
38 visceral leishmaniasis 31.0 IL4 IL10 IFNG
39 vernal keratoconjunctivitis 31.0 RNASE3 IL5 IL4 IL13 CCL5 CCL11
40 chlamydia 31.0 IL4 IL10 IFNG
41 poliomyelitis 31.0 IL4 IL10 IFNG
42 toxoplasmosis 31.0 IL4 IL10 IFNG
43 intestinal schistosomiasis 31.0 IL5 IL4 IL13
44 allergic rhinitis 31.0 RNASE3 IL5 IL4 IL13 IL10 IGHE
45 q fever 31.0 IL4 IL10 IFNG
46 trichinosis 30.9 IL9 IL5 IL4
47 hyper ige syndrome 30.9 IL4 IGHE IFNG
48 cephalosporin allergy 30.9 IL5 IL10 IFNG
49 coccidiosis 30.9 IL4 IL10 IFNG
50 otitis media 30.9 RNASE3 IL4 IL10 IGHE CCL11

Graphical network of the top 20 diseases related to Allergic Hypersensitivity Disease:



Diseases related to Allergic Hypersensitivity Disease
Sources

Symptoms & Phenotypes for Allergic Hypersensitivity Disease

About this section

UMLS symptoms related to Allergic Hypersensitivity Disease:


nausea and vomiting, abdominal pain, pruritus, tinnitus, syncope, stridor, snoring, sore throat, exanthema, coughing, vertigo/dizziness, equilibration disorder, signs and symptoms of ill-defined conditions, (non-specific) malaise and fatigue, injection site hypersensitivity, fever of unknown origin

MGI Mouse Phenotypes related to Allergic Hypersensitivity Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10 CCL11 CCL17 CCL5 CCR3 EPX FCER2
2 digestive/alimentary MP:0005381 9.8 FCER2 IFNG IL10 IL13 IL4 IL5
3 immune system MP:0005387 9.8 CCL11 CCL17 CCL5 CCR3 EPX FCER2
4 respiratory system MP:0005388 9.17 CCL11 CCR3 IFNG IL10 IL13 IL4
Sources

Drugs & Therapeutics for Allergic Hypersensitivity Disease

About this section

PubMed Health treatment related to Allergic Hypersensitivity Disease: 63

The best way to prevent allergic reactions is to avoid contact with the triggers (allergens). How well this works will mainly depend on the type of trigger. It’s often quite easy to avoid contact with things like certain foods or chemical substances. It’s almost impossible to avoid pollen, though. But pollen calendars and forecasts, for instance on the internet, can give you an idea of the pollen count in certain regions. People with dust mite allergies can somewhat lower their exposure to dust mites in their home by taking precautions such as using mite-proof bedding and removing "dust traps." The symptoms of many allergies can be treated with medication. Antihistamines and steroids are often used for this purpose. These medications are available in various forms, including tablets, nasal sprays and injections. They are mainly used in the treatment of allergic rhinitis (in the nose) and allergic conjunctivitis (in the eyes). Allergic reactions affecting the skin are also treated using steroid ointments or creams. A treatment known as allergen-specific immunotherapy (“desensitization”) can help reduce sensitivity to some allergens in the long term. Like with vaccines, this treatment approach involves exposing people to small amounts of the allergen. Here it is done at regular intervals by either injecting the allergen into your skin or placing it under your tongue. It takes about three to five years to complete allergen-specific immunotherapy. This approach is mainly used for the treatment of allergies to pollen (hay fever), dust mites and insect venom. There is currently no evidence that herbal or homeopathic products can help in the treatment of allergies. This is also true for acupuncture.

Drugs for Allergic Hypersensitivity Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1361)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ketotifen Approved Phase 4 34580-13-7, 34580-14-8 3827
2
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
3
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
4
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
5
Mycophenolic acid Approved Phase 4 24280-93-1 446541
6
Atenolol Approved Phase 4 29122-68-7 2249
7
Dapsone Approved, Investigational Phase 4 80-08-0 2955
8
Cyproheptadine Approved Phase 4 129-03-3 2913
9
Nifedipine Approved Phase 4 21829-25-4 4485
10
Resveratrol Approved, Experimental, Investigational Phase 4 501-36-0 445154
11
Reboxetine Approved, Experimental Phase 4 98769-81-4, 71620-89-8 123628 65856
12
Indomethacin Approved, Investigational Phase 4 53-86-1 3715
13
Fludrocortisone Approved, Investigational Phase 4 127-31-1 31378
14
Losartan Approved Phase 4 114798-26-4 3961
15
Scopolamine Approved, Investigational Phase 4 6533-68-2, 51-34-3 5184
16
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
17
Cobicistat Approved Phase 4 1004316-88-4
18
Rilpivirine Approved Phase 4 500287-72-9
19
Esmolol Approved Phase 4 103598-03-4, 81147-92-4 59768
20
Trimetazidine Approved, Investigational Phase 4 5011-34-7
21
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
22
Basiliximab Approved, Investigational Phase 4 152923-56-3, 179045-86-4
23
Eplerenone Approved Phase 4 107724-20-9 150310 443872
24
Ampicillin Approved, Vet_approved Phase 4 69-53-4 6249
25
Heparin Approved, Investigational Phase 4 9005-49-6 46507594 772
26
Teicoplanin Approved, Investigational Phase 4 61036-62-2
27
Petrolatum Approved, Investigational Phase 4 8009-03-8
28
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
29
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
30
Mannitol Approved, Investigational Phase 4 69-65-8 453 6251
31
Fluocinolone Acetonide Approved, Investigational, Vet_approved Phase 4 67-73-2 6215
32
Neomycin Approved, Vet_approved Phase 4 1404-04-2 8378
33
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
34
Bepotastine Approved Phase 4 125602-71-3, 190786-44-8 2350
35
Dimenhydrinate Approved Phase 4 523-87-5 441281
36
Cetirizine Approved Phase 4 83881-51-0 2678
37
Levocetirizine Approved Phase 4 130018-77-8 1549000
38
Wormwood Approved, Experimental Phase 4
39
Ertapenem Approved, Investigational Phase 4 153832-46-3 150610
40
Pyrazinamide Approved, Investigational Phase 4 98-96-4 1046
41
Calcium carbonate Approved, Investigational Phase 4 471-34-1
42
Benzoyl peroxide Approved Phase 4 94-36-0 7187
43
Silicon Approved, Investigational Phase 4 7440-21-3 4082203
44
Desloratadine Approved, Investigational Phase 4 100643-71-8 124087
45
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
46
Loratadine Approved, Investigational Phase 4 79794-75-5 3957
47
Lumefantrine Approved Phase 4 82186-77-4 6437380
48
Artemether Approved Phase 4 71963-77-4 68911 119380
49
Nepafenac Approved, Investigational Phase 4 78281-72-8 151075
50
Mupirocin Approved, Investigational, Vet_approved Phase 4 12650-69-0 446596

Interventional clinical trials:

(show top 50) (show all 4815)
# Name Status NCT ID Phase Drugs
1 Evaluation Whether Higher Retention Rate is in Those of Combined Methadone With N-Acetyl-Cysteine Compared to Those With Methadone Alone During a Six-month Study Unknown status NCT01047956 Phase 4 Methadone; NAC;Methadone
2 Cross-reactivity and Tolerability of Ertapenem in Patients With IgE-mediated Allergy to Beta-lactams Unknown status NCT01159379 Phase 4 ertapenem
3 Botulinum Toxin to Improve Lower Blepharoplasty Scar Unknown status NCT02786550 Phase 4 Botulinum Toxin
4 A Double Blind Placebo Controlled Randomised Trial to Study the Effects of Birch Pollen Specific Immunotherapy (BP-SIT) on the Symptoms of the Oral Allergy Syndrome in Adult Patients Unknown status NCT01431859 Phase 4
5 Comparison of Tolerability Between Two Allergy Drops Unknown status NCT01390961 Phase 4 alacaftadine and naphazoline HCl & pheniramine maleate
6 Bronchiolitis All-study, SE-Norway What is the Optimal Inhalation Treatment for Children 0-12 Months With Acute Bronchiolitis? Unknown status NCT00817466 Phase 4 Racemic adrenaline;Isotonic saline
7 Effect of Mosapride on Postoperative Ileus in Patients Undergoing Colorectal Surgery Unknown status NCT02056405 Phase 4 Mosapride;Placebo
8 Single Centre,Randomized,Phase IV Study to Assess the Topical r-Hirudin (Thrombexx)Efficacy in the Patients With Haematomas Unknown status NCT01960569 Phase 4 active product ( Thrombexx) assigned to arm 1
9 Prospective, Randomized, Open-label, Controlled Trial of Cyclooxygenase-2 Inhibitor (Celecoxib; Celebrex®) for Adjuvant Anticancer Effect in Patients With Biliary-pancreas Cancer. Unknown status NCT01111591 Phase 4 Cox2 inhibitor (Celecoxib)
10 To Assess the Impact of Ocular Allergy Treatment on Patients Using an Opthalmic Agent (or no Treatment) Versus Alcaftadine(Lastacaft™) Unknown status NCT01808768 Phase 4 Alcaftadine
11 An Open Pilot Study to Evaluate the Efficacy and Safety, Tolerability of Raltegravir（RAL）in Treatment-experienced HIV-1 Infected Adult Chinese Patients Unknown status NCT01201239 Phase 4 raltegravir
12 Efficacy of Systemic Glucocorticoid in the Treatment of Wheezing in Children Unknown status NCT00494624 Phase 4 prednisolone
13 A Phase IV, Randomised, Multicentre, Double-blind, Study to Evaluate the Clinical Utility of Prospective Genetic Screening (HLA-B*1301) for Susceptibility to Dapsone Hypersensitivity Syndrome Unknown status NCT02550080 Phase 4 Dapsone
14 Evaluation of Long-term Clinical Efficacy of House Dust Mite Immunotherapy in Children With Bronchial Asthma Unknown status NCT00496574 Phase 4
15 Immunological Mechanisms of Oralair® (5 Grass Mix Sublingual Allergen Immunotherapy Tablet) in Patients With Seasonal Allergic Rhinitis Unknown status NCT02014623 Phase 4 Control
16 Bacteria and Cytokines as Factors Modulating Visceral Afferent Processing in Irritable Bowel Syndrome: Manipulation of Intestinal Bacteria and Mucosal Cytokines by Probiotic Therapy and the Effect on Visceral Hypersensitivity Unknown status NCT00418340 Phase 4 probiotic (bacterial/dietary supplement)
17 Effectiveness of Nano-hydroxyapetite Care Paste in Reducing Dentinhypersenstitivity: A Double Blind Randomized Control Trial Unknown status NCT02936830 Phase 4 5% Sodium Fluoride Varnish;15% Nanohydroxyapetite paste;Glycerol
18 Recovery of Muscle Function After Deep Neuromuscular Block by Means of Dia-phragm Ultrasonography and Adductor Pollicis Acceleromyography: Comparison of Neostigmine vs. Sugammadex as Reversal Drugs. Unknown status NCT02698969 Phase 4 Sugammadex;Neostigmine;Atropine;Rocuronium;Fentanyl;Propofol;Sevoflurane
19 A Placebo-Controlled, Double-Blind, Cross-Over Study With Rupatadine 10 Mg in 30 Mosquito-Bite Allergic Adult Subjects Unknown status NCT00258141 Phase 4 Rupatadine;Placebo
20 A Prospective Multicenter Trial Evaluating Helios Biodegradable Polymer Sirolimus-eluting Stent Safety and Effectiveness in Treatment of Coronary Artery Disease Unknown status NCT01880879 Phase 4
21 Evaluation of Early Clinical and Immunological Efficacy of Specific Immunotherapy to Dust Mites in Children With Asthma Unknown status NCT00496561 Phase 4
22 The Relationship Between Gastroesophageal Reflux and Pediatric Rhinitis: Significance of Pale/Blue Colored Turbinate. A Randomized Controlled Trial Unknown status NCT02278081 Phase 4 lansoprazole;placebo
23 The Effects of Xolair (Omalizumab) on Airway Hyperresponsiveness Unknown status NCT00208234 Phase 4 Omalizumab;Placebo for Omalizumab;omalizumab
24 The Effect of Xolair on Inhibiting Leukotriene and Cytokine (IL-4 and IL-13) Release From Blood Basophils Unknown status NCT00673218 Phase 4 Placebo;Xolair
25 Intravenous Paracetamol Versus Intravenous Dexketoprofen in Patients Presented With Dysmenorrhea in Emergency Department Unknown status NCT02373514 Phase 4 Paracetamol;Dexketoprofen
26 Acthar as Rescue Therapy for Transplant Glomerulopathy in Kidney Transplant Recipients Unknown status NCT02057523 Phase 4 Acthar
27 CLINICAL MANAGEMENT OF CHILDHOOD INTESTINAL LYMPHOID NODULAR HYPERPLASIA: A RANDOMIZED CONTROLLED CLINICAL TRIAL. Unknown status NCT01789294 Phase 4 Mesalamine
28 Gadolinium Enhanced Dual-Energy Computed Tomography: A Feasibility Study to Assess Image Quality and Diagnostic Confidence Unknown status NCT02163005 Phase 4 Gadolinium
29 Atomization of Fentanyl: A Randomized Comparison Study of Intranasal Versus Intravenous Fentanyl for Pre-hospital Pain Management Unknown status NCT00882960 Phase 4 intravenous fentanyl;intra-nasal fentanyl
30 Changes in Exhaled Breath Temperature During the Pollen Season in Subjects With Allergic Rhinoconjunctivitis Sensitized to Grasses and Effect of Sublingual Immunotherapy Unknown status NCT01785394 Phase 4 5 grass allergen extract
31 Randomized, Double Blind, Placebo Control Trial to Evaluate the Efficacy of Wu-Chu-Yu Tang on Gastroesophageal Reflux Disease (GERD) Unknown status NCT01822106 Phase 4
32 Effect of Escitalopram vs. Reboxetine on Somatic and Visceral Sensitivity of Patients With Major Depressive Disorder: a Randomized, Double Blind Clinical Trial Unknown status NCT00209807 Phase 4 escitalopram;Reboxetine
33 Effects of Pioglitazone on Body Composition,Insulin Sensitivity and Protein Metabolism in ESRD Non Diabetic Individuals Unknown status NCT01253928 Phase 4 Pioglitazone
34 A MULTICENTRE RANDOMIZED CONTROLLED CLINICAL TRIAL ON THE EFFICACY OF TEGADERM CHG IN REDUCING CATHETER RELATED BLOOD STREAM INFECTIONS Unknown status NCT01142934 Phase 4
35 Comparison of Different Doses of Remifentanil on Postoperative Pain in Patients Undergoing Thyroidectomy: a Prospective, Double-blinded Randomized Control Trial Unknown status NCT01761149 Phase 4 Remifentanil
36 N-Acetylcysteine to Prevent Contrast-Induced Nephropathy in Acute Coronary Syndromes Unknown status NCT00939913 Phase 4 intravenous NAC;Placebo
37 SINOL + MucoAd™ (SMAN) Evaluation Trial: A Double-Blind, Cross-Over Comparison of SINOL and SMAN in Subjects With Congestion Due to Allergic Rhinitis Unknown status NCT00825656 Phase 4 Sinol or Sinol-M nasal spray
38 A Randomized Controlled Trial Comparing the Adductor Canal Catheter (ACC) and Intra-articular Catheter (IAC) Following Primary Total Knee Arthroplasty Unknown status NCT02497911 Phase 4 Ropivicaine;Bupivicaine
39 A Randomized Double-blind Study to Evaluate the Effect of Linagliptin on Pancreatic Beta Cell Function and Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus on Metformin Monotherapy Unknown status NCT02097342 Phase 4 Linagliptin;Placebo;Voglibose
40 Fludrocortisone's Test in the Identification of Salt Sensitivity Unknown status NCT01453959 Phase 4 Fludrocortisone
41 Acute Effects of an Oral Fat Load on Skeletal Muscle and Hepatic Insulin Sensitivity (FLAME-study) Unknown status NCT01736202 Phase 4
42 Randomized Controlled Trial Testing the Effect of Milk Formula Supplemented With L. Reuteri on Crying Time in Colicky Infants Less Than 3 Months Old Unknown status NCT02430831 Phase 4
43 Study the Effect of Intravenous Hyoscine Butylbromide Injection on the Duration and Progress of First Stage Labour in High Risk Women Unknown status NCT03055390 Phase 4 hyoscine butylbromide;placebo
44 Effects of N-Acetyl-Cysteine on Oxidative Stress Biomarkers in Bipolar Patients With and Without Tobacco Use Disorder Unknown status NCT02252341 Phase 4
45 Diagnostic Immunization With Rabies Vaccine in Patients With Primary Immunodeficiency Disorders Unknown status NCT02490956 Phase 4
46 Effectiveness of Low Level Laser at the Auriculotherapy Points, in Reducing Postoperative Pain in Third Molar Surgery Unknown status NCT02657174 Phase 4
47 Randomized Controlled Study to Evaluate the Efficacy of Pravastatin on Survival and Recurrence of Advanced Gastroesophageal Cancer Unknown status NCT01038154 Phase 4 Pravastatin
48 The Effect of Bupivacaine (Marcaine) in Reducing Early Post Tonsillectomy Pain Unknown status NCT01582022 Phase 4 Bupivacaine;normal saline
49 The Effect of Tocilizumab on the Cellular Immune Response to Seasonal Influnza Vaccine in Patients With Rheumatoid Arthritis Unknown status NCT01980836 Phase 4
50 Hypervolemia and Treatment Guided by Bioimpedance in End Stage Renal Disease Patients in Zonguldak (Prospective Study) Unknown status NCT01468363 Phase 4

Search NIH Clinical Center for Allergic Hypersensitivity Disease

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Brompheniramine
Budesonide
Carbinoxamine
Chlorcyclizine
Chlorpheniramine
Cyproheptadine
Dexbrompheniramine
Dexchlorpheniramine maleate
Diphenhydramine
Human Serum Albumin
Mepyramine
Methylprednisolone
methylprednisolone acetate
Methylprednisolone Sodium Succinate
prednisolone
prednisolone acetate
PREDNISOLONE ACETATE PWDR
PREDNISOLONE PWDR
Prednisolone sodium phosphate
prednisolone tebutate
Prednisone
PREDNISONE PWDR
Promethazine

Cochrane evidence based reviews: hypersensitivity

Sources

Genetic Tests for Allergic Hypersensitivity Disease

About this section
Sources

Anatomical Context for Allergic Hypersensitivity Disease

About this section

MalaCards organs/tissues related to Allergic Hypersensitivity Disease:

41
Testes, Skin, T Cells, Lung, Breast, Bone, Prostate
Sources

Publications for Allergic Hypersensitivity Disease

About this section

Articles related to Allergic Hypersensitivity Disease:

(show top 50) (show all 30973)
# Title Authors PMID Year
1
IL-17 amplifies human contact hypersensitivity by licensing hapten nonspecific Th1 cells to kill autologous keratinocytes. 9 38
20357258 2010
2
IgE, mast cells, basophils, and eosinophils. 9 38
20176269 2010
3
Genetic determinants of both ethanol and acetaldehyde metabolism influence alcohol hypersensitivity and drinking behaviour among Scandinavians. 9 38
20205700 2010
4
Evidence for the involvement of free light chain immunoglobulins in allergic and nonallergic rhinitis. 9 38
19818484 2010
5
Immediate and delayed reactions to radiocontrast media: is there an allergic mechanism? 9 38
19563991 2009
6
Hypersensitivity to proton pump inhibitors: lansoprazole-induced Kounis syndrome. 9 38
18378022 2009
7
Correlation between atopy and hypersensitivity reactions during therapy with three different TNF-alpha blocking agents in rheumatoid arthritis. 9 38
19473578 2009
8
Reduced incidence of insect-bite hypersensitivity in Icelandic horses is associated with a down-regulation of interleukin-4 by interleukin-10 and transforming growth factor-beta1. 9 38
18082270 2008
9
CD69 upregulation on T cells as an in vitro marker for delayed-type drug hypersensitivity. 9 38
18005225 2008
10
Hypersensitivity reactions to biological agents with special emphasis on tumor necrosis factor-alpha antagonists. 9 38
17873578 2007
11
[Type IV of hypersensitivity and its subtypes]. 9 38
18409354 2007
12
[Contribution of indicators of sensitized T lymphocytes in the diagnosis of IgE independent and IgE dependent cow's allergy in children]. 9 38
17965461 2007
13
Phenotypic diversity in delayed drug hypersensitivity: an immunologic explanation. 9 38
17008937 2006
14
Abacavir hypersensitivity reaction in primary HIV infection. 9 38
16816555 2006
15
T cell-mediated hypersensitivity to quinolones: mechanisms and cross-reactivity. 9 38
16393267 2006
16
Intracellular cytokines may model immunoregulation of abacavir hypersensitivity in HIV-infected subjects. 9 38
15867870 2005
17
The application of a monoclonal antibody to CD62L on paraffin-embedded tissue samples in the assessment of the cutaneous T-cell infiltrates. 9 38
15660650 2005
18
Hypersensitivity to hydrolyzed cow's milk protein formula in infants and young children with atopic eczema/dermatitis syndrome with cow's milk protein allergy. 9 38
16358982 2005
19
Anti-IgE therapy. 9 38
15474858 2004
20
Fondaparinux: a suitable alternative in cases of delayed-type allergy to heparins and semisynthetic heparinoids? A study of 7 cases. 9 38
15373846 2004
21
Relationship between peach lipid transfer protein specific IgE levels and hypersensitivity to non-Rosaceae vegetable foods in patients allergic to lipid transfer protein. 9 38
14989398 2004
22
Therapeutic potential of Janus kinase 3 (JAK3) inhibitors. 9 38
15180539 2004
23
Quantitative assessment of immediate cutaneous hypersensitivity in a mouse model exhibiting an IgE response to Timothy grass allergens. 9 38
14646968 2003
24
Do the clinical responses and complications following etanercept or infliximab therapy predict similar outcomes with the other tumor necrosis factor-alpha antagonists in patients with rheumatoid arthritis? 9 38
14677170 2003
25
Hypersensitivity to aldesleukin (interleukin-2 and proleukin) presenting as facial angioedema and erythema. 9 38
12974198 2003
26
Specific delayed-type hypersensitivity responses to ESAT-6 identify tuberculosis-infected cattle. 9 38
12734217 2003
27
Protective effects of a recombinant fragment of human surfactant protein D in a murine model of pulmonary hypersensitivity induced by dust mite allergens. 9 38
12706535 2003
28
L-selectin or ICAM-1 deficiency reduces an immediate-type hypersensitivity response by preventing mast cell recruitment in repeated elicitation of contact hypersensitivity. 9 38
12682269 2003
29
Hypersensitivity to mugwort (Artemisia vulgaris) in patients with peach allergy is due to a common lipid transfer protein allergen and is often without clinical expression. 9 38
12170274 2002
30
Influence of human T-cell lymphocytotropic virus type 1 infection on serologic and skin tests for strongyloidiasis. 9 38
11716123 2001
31
Phenotypic characterization of human CD4+ regulatory T cells obtained from cutaneous dinitrochlorobenzene-induced delayed type hypersensitivity reactions. 9 38
11511310 2001
32
TNFalpha promoter region gene polymorphisms in carbamazepine-hypersensitive patients. 9 38
11294926 2001
33
Tumor necrosis factor-alpha promoter polymorphism TNF2 is associated with a stronger delayed-type hypersensitivity reaction in the skin of borderline tuberculoid leprosy patients. 9 38
11261930 2001
34
Mast cells control neutrophil recruitment during T cell-mediated delayed-type hypersensitivity reactions through tumor necrosis factor and macrophage inflammatory protein 2. 9 38
11085746 2000
35
Assessment of latex allergy in a healthcare population: are the available tests valid? 9 38
10998022 2000
36
Expression of IFNgamma, coexpression of TNFalpha and matrix metalloproteinases and apoptosis of T lymphocytes and macrophages in granuloma annulare. 9 38
10994772 2000
37
Il-4 and IFN-gamma mRNA induction in human peripheral lymphocytes specific for beta-lactam antibiotics in immediate or delayed hypersensitivity reactions. 9 38
10821462 2000
38
Use of alkaline rinsing solution to prevent hypersensitivity reactions during hemodialysis: data from a multicentre retrospective analysis. 9 38
10626828 1999
39
Induction and regulation of the IgE response. 9 38
10586891 1999
40
Targeting Janus kinase 3 in mast cells prevents immediate hypersensitivity reactions and anaphylaxis. 9 38
10480916 1999
41
Des-Arg9-bradykinin metabolism in patients who presented hypersensitivity reactions during hemodialysis: role of serum ACE and aminopeptidase P. 9 38
10458510 1999
42
Relevance of pollen-specific IgE levels to the development of Apiaceae hypersensitivity in patients with birch pollen allergy. 9 38
9201368 1997
43
Increased soluble ICAM-1 concentration and impaired delayed-type hypersensitivity skin tests in patients with chronic liver disease. 9 38
9059357 1997
44
An essential role for macrophage migration inhibitory factor in the tuberculin delayed-type hypersensitivity reaction. 9 38
8551232 1996
45
Expression and inducibility of antigens in severe combined immunodeficient mice recognized by human anti-P450 antibodies. 9 38
7482543 1995
46
Hypersensitivity reactions to chemotherapy agents in patients receiving chemoimmunotherapy with high-dose interleukin 2. 9 38
7666481 1995
47
Allergy to ingested cereals in atopic children. 9 38
7535982 1994
48
Clonal analysis of lung and blood T cells in patients with sarcoidosis. 9 38
8016795 1994
49
Pentoxifylline suppresses irritant and contact hypersensitivity reactions. 9 38
8409522 1993
50
Cytokines and their role in the pathogenesis of severe food hypersensitivity reactions. 9 38
8214800 1993
Sources

Variations for Allergic Hypersensitivity Disease

About this section

ClinVar genetic disease variations for Allergic Hypersensitivity Disease:

6
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 46;XX;t(4;14)(p15.2;q13)dn Translocation Likely pathogenic
2 SLC9A6 NM_001042537.1(SLC9A6): c.1346C> A (p.Ala449Glu) single nucleotide variant Uncertain significance rs1556619324 X:135098913-135098913 X:136016754-136016754
3 GFOD1 ; MCUR1 ; NOL7 ; PHACTR1 ; RANBP9 ; RNF182 ; SIRT5 ; TBC1D7 GRCh37/hg19 6p24.1-23(chr6: 12536624-13968949) copy number gain Uncertain significance 6:12536624-13968949 :0-0
Sources

Expression for Allergic Hypersensitivity Disease

About this section
Search GEO for disease gene expression data for Allergic Hypersensitivity Disease.
Sources

Pathways for Allergic Hypersensitivity Disease

About this section

Pathways related to Allergic Hypersensitivity Disease according to GeneCards Suite gene sharing:

(show all 37)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 66
Show member pathways
 14.04 RNASE3 IL9 IL5 IL4 IL3 IL13
2
ERK Signaling 64
Show member pathways
 13.87 IL9 IL5 IL4 IL3 IL13 IL10
3
PEDF Induced Signaling 64
Show member pathways
 13.73 IL9 IL5 IL4 IL3 IL13 IL10
4
TGF-Beta Pathway 64
Show member pathways
 13.55 IL9 IL5 IL4 IL3 IL13 IL10
5
Akt Signaling 64
Show member pathways
 13.47 IL9 IL5 IL4 IL3 IL13 IL10
6
Cytokine Signaling in Immune system 66
Show member pathways
 13.42 IL9 IL5 IL4 IL3 IL13 IL10
7
PAK Pathway 64
Show member pathways
 13.33 IL9 IL5 IL4 IL3 IL13 IL10
8
Allograft rejection 37 1
Show member pathways
 12.9 RNASE3 IL9 IL5 IL4 IL3 IL13
9
CCR5 Pathway in Macrophages 64
Show member pathways
 12.83 HRH4 CCR3 CCL5 CCL17 CCL11
10
Pathways in cancer 37
12.79 IL5 IL4 IL3 IL13 IFNG
11
Th17 cell differentiation 37
Show member pathways
 12.6 IL5 IL4 IL13 IL10 IFNG
12
NF-kappaB Signaling 4
12.6 TPT1 IL4 IL3 IL10 IFNG CCL5
13
Immune response Fc epsilon RI pathway 22
Show member pathways
 12.59 IL5 IL4 IL3 IL13 IGHE
14
T cell receptor signaling pathway 37
Show member pathways
 12.58 IL9 IL5